GlassScriptPhysician profile
Kerri Ruddell
NPI 1174183578
$1,531.26
in general payments reported to CMS, 2019-2025
19 companies · $18.66 in 2025
The $18.66 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $317 · 2022: $277 · 2023: $642 · 2024: $277 · 2025: $18.66.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $938.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $938.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $189.15 | 2021-2024 | Wegovy |
| Teva Pharmaceuticals USA, INC. | $177.67 | 2022-2023 | Austedo Xr, Uzedy, Austedo |
| Glaxosmithkline, LLC. | $163.26 | 2021-2024 | Trelegy Ellipta |
| Boston Scientific Corporation | $139.59 | 2023 | Watchman Access System |
| Axsome Therapeutics, INC. | $124.99 | 2023 | Auvelity |
| Otsuka America Pharmaceutical, INC. | $103.33 | 2022-2024 | Abilify Maintena, Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $102.46 | 2022-2023 | |
| Astrazeneca Pharmaceuticals LP | $90.58 | 2021-2024 | Tezspire, Airsupra |
| Alkermes, INC. | $74.18 | 2022-2024 | Aristada, Lybalvi |
| Pfizer INC. | $68.34 | 2024-2025 | |
| Neurocrine Biosciences, INC. | $65.53 | 2022-2024 | Ingrezza, Ongentys |
| Lilly USA, LLC | $46.70 | 2024 | Mounjaro, Zepbound, Jardiance |
| Indivior INC. | $40.63 | 2022 | |
| Abbvie INC. | $37.12 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.33 | 2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $26.93 | 2024 | Cologuard Collection Kit |
| Sanofi-Aventis U.S. LLC | $19.49 | 2021 | |
| Astellas Pharma US INC | $15.36 | 2021 | |
| Amgen INC. | $14.62 | 2024 | Otezla, Repatha |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kerri Ruddell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.